Sprint Bioscience AB (publ) (OM: SPRINT)
Health Care · Biotechnology · SE
Skr3.15
-0.63% today · +430.1% 1Y
Sprint Bioscience AB (publ) (OM: SPRINT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $35.32M and employs 30 people.
Over the last twelve months the share price has gained 430.1%, trading between 0.51 and 4.59.
Tweenvest scores Sprint Bioscience AB (publ) across four factors: quality 63/100, value 32/100, growth 100/100. Its strongest factor is growth.
SPRINT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $35.32M
- Revenue (TTM)
- $16.11M
- P/E
- 3.85
- EPS
- 0.82
- Dividend yield
- —
- Beta (5Y)
- -0.50
- 52-week high
- Skr4.59
- 52-week low
- Skr0.51
- Avg volume (3M)
- —
- Shares outstanding
- 105.52M
- Employees
- 30
- Next earnings
- —
About Sprint Bioscience AB (publ)
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. The company was incorporated in 2009 and is based in Huddinge, Sweden.
- ISIN
- SE0006343745
- Founded
- 2009
- Listed since
- Nov 7, 2014
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.